Merck’s TROP2 ADC Teams Up With Keytruda, Sending a New Signal in the First-Line Lung Cancer Arena

In first-line treatment for non-small cell lung cancer, the truly difficult threshold is often not whether a therapy is better than placebo or a weak comparator, but whether it can hold its ground against existing standard therapy. The TROP2 antibody-drug conjugate sacituzumab tirumotecan, backed by Merck and its partner Kelun-Biotech, has now produced positive results in a global trial as part of a combination with Keytruda, giving this competition a signal with greater clinical weight.

According to Investor's Business Daily, the study enrolled previously untreated patients with non-small cell lung cancer and tested sacituzumab tirumotecan plus Keytruda against the standard of care of Keytruda combined with chemotherapy. The trial results showed that the ADC-and-immunotherapy combination improved progression-free survival, meaning the length of time patients maintained treatment benefit without disease progression.

What makes this design important is that the control group was not Keytruda monotherapy, but the chemotherapy-containing Keytruda combination commonly used in Western clinical practice. In other words, Merck was not merely proving that the ADC has activity against a lower bar; it placed the new combination into the most crowded and most practical setting in first-line lung cancer treatment: physicians already have immunochemotherapy regimens that can extend survival, and any new therapy must prove that it is worth changing established habits.

Sacituzumab tirumotecan is a TROP2-directed antibody-drug conjugate. This class of drugs uses antibodies to recognize markers on the surface of tumor cells, then delivers a cytotoxic payload near cancer cells in an effort to improve the selectivity of cell killing. The rationale for combining it with an immune checkpoint inhibitor such as Keytruda is to apply two kinds of pressure at once: direct cytotoxic killing and immune activation. But whether such a combination can deliver sufficiently clear efficacy with tolerable side effects has always required large-scale clinical data to answer.

Publicly available information on the same event remains limited. The report focused on the improvement in progression-free survival and did not provide full numerical data, patient subgroups, overall survival results, or detailed safety data. Therefore, this readout is better understood as a key directional win, rather than a conclusion that the treatment landscape has already been rewritten. For first-line lung cancer, the clinical significance will become more concrete only if subsequent data can show which patients benefit most and whether toxicity is lower than, or at least not worse than, chemotherapy combinations.

Capital markets reacted first, with Merck’s share price rising on the data, reflecting investor expectations for the ADC-plus-immunotherapy approach. For Merck, although Keytruda remains a core oncology immunotherapy product, future growth requires more new drugs that can be paired with it and extend its treatment reach. If the Kelun collaboration can establish itself in first-line lung cancer, it would bring the TROP2 ADC closer to a large commercial oncology market, beyond being a popular technology platform.

The history of lung cancer treatment is often advanced gradually by small but reliable clinical differences, rather than overturned instantly by a single news event. These results push the question into the next stage: can ADCs not only fill a role in later lines of therapy, but truly challenge the place of chemotherapy in first-line treatment? The answer still depends on full data, regulatory review, and the gradual unfolding of clinical adoption, but Merck has at least made that question harder to ignore.